<DOC>
	<DOCNO>NCT02796261</DOCNO>
	<brief_summary>The purpose study compare efficacy safety eflornithine combination lomustine , compare lomustine take alone , treat patient whose anaplastic astrocytoma recurred/progressed radiation temozolomide chemotherapy .</brief_summary>
	<brief_title>Study Evaluate Eflornithine + Lomustine v Lomustine Recurrent Anaplastic Astrocytoma ( AA ) Patients</brief_title>
	<detailed_description>This study consist 4 study period 50 month total , consist : Screening Period - A maximum screening duration 4 week . Treatment Period - Treatment Arm A 24 month ; Treatment Arm B 12 month . End Treatment Visit - A minimum 4 week post last treatment arm . Follow-Up Period - Up 24 month . A total approximately 280 patient randomize 1:1 ratio receive either eflornithine + lomustine lomustine alone .</detailed_description>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible participation study : Surgical biopsyproven diagnosis WHO grade 3 AA . Unequivocal evidence first AA tumor progression recurrence ≤ 3 month prior randomization base MRI criterion tumor progression use enlarge Gdcontrast enhancement and/or T2 hypersensitivity ( Appendix 4 ) . Patients nonmeasurable Gd contrast enhance tumor eligible necrosis see MRI and/or histopathological confirmation AA per standard care procedure obtain within 4 week prior randomization . First tumor progression recurrence follow surgical resection biopsy , resection feasible , EBRT temozolomide chemotherapy . Completion EBRT ≥ 6 month prior randomization . A patient whose AA tumor progress recur another surgical resection prior randomization eligible ) pathology review confirm AA , b ) postsurgical MRI demonstrate measurable tumor T2/FLAIR , c ) MRI perform surgery within 4 week prior randomization . Karnofsky Performance Status ( KPS ) score &gt; 70 . Patients meet follow exclusion criterion eligible study participation : MRI define progression consistent diagnosis glioblastoma radiation necrosis . Patients consider refractory EBRT temozolomide progress . Prior systemic therapy recurrence AA . Presence extracranial leptomeningeal disease . Prior lomustine use . Any clinical condition prior therapy , opinion Investigator , would make patient unsuitable study . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Grade 3 Glioma</keyword>
	<keyword>Glioma</keyword>
	<keyword>Eflornithine</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Neuro-oncology</keyword>
	<keyword>Progressive Anaplastic Astrocytoma</keyword>
	<keyword>Recurrent Anaplastic Astrocytoma</keyword>
	<keyword>Progressive Glioma</keyword>
	<keyword>Recurrent Glioma</keyword>
	<keyword>Malignant Glioma</keyword>
	<keyword>Progressive Brain Tumor</keyword>
	<keyword>Recurrent Brain Tumor</keyword>
</DOC>